Our dedicated R&D building is a hub of innovation, purpose-built to drive excellence in research and development pipeline. It features best-in-class  laboratories equipped with state-of-the-art technology, including high-throughput bioreactor systems (Ambr^® 15 and Ambr^® 250), lab bench glass bioreactors, Cobas^® analyzer (for clinical chemistry and immunochemistry assays), multiple chromatographic systems, and cutting-edge equipment for Cell Line Development, enabling us to deliver exceptional support for our comprehensive range of development services. These advanced CDMO facilities provide an optimized environment for conducting experiments, analyzing data, and creating innovative solutions that propel projects from concept to realization.

In addition to housing our cutting-edge research laboratories, the R&D building is also home to our Regulatory department, strategically positioned to foster seamless communication and collaboration between multidisciplinary teams. This close integration ensures streamlined workflows, accelerates decision-making, and supports the development of projects in full compliance with regulatory standards.

Our EU GMP-certified facilities are built to meet the highest standards of pharmaceutical production, featuring a dedicated GMP area for the production of early-phase clinical batches. With specialized expertise in mammalian cell culture and microbial manufacturing, our infrastructure ensures flexibility and precision to support diverse therapeutic pipelines.​

Designed to incorporate advanced single-use technology, our GMP area offers the potential for optimized processes that minimize contamination risks and improve turnaround times. This approach is particularly suited for early-phase clinical trials, enabling scalable, efficient, and compliant solutions for producing clinical trial materials.​

Our facilities are designed to support the rigorous demands of preclinical development, featuring multiple buildings certified for Good Laboratory Practices (GLP). These purpose-built spaces are tailored to ensure the highest levels of quality, compliance, and reproducibility in preclinical studies, setting the foundation for reliable and meaningful data.​

​Equipped with advanced infrastructure, our GLP-certified buildings provide specialized environments for conducting a wide range of preclinical studies, including pharmacokinetics, toxicology, and efficacy evaluations. A key feature of our preclinical CDMO  facilities is the integration of proprietary animal models, which are developed to mimic specific conditions. These models enable precise and predictive insights into the safety and efficacy of drug candidates, accelerating the transition from discovery to clinical phases.